TG Therapeutics Inc
SWB:NKB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
TG Therapeutics Inc
SWB:NKB2
|
US |
|
B
|
Bastei Luebbe AG
XHAM:BST
|
DE |
|
Anadolu Efes Biracilik ve Malt Sanayii AS
OTC:AEBZY
|
TR |
|
G
|
Greenfire Resources Ltd
TSX:GFR
|
CA |
|
Weimob Inc
F:36W
|
CN |
|
S
|
Steyr Motors AG
XMUN:4X0
|
AT |
|
Takashimaya Co Ltd
F:DC9
|
JP |
|
NAHL Group PLC
OTC:NHLPF
|
UK |
|
N
|
Nahar Capital and Financial Services Ltd
BSE:532952
|
IN |
|
Hewlett Packard Enterprise Co
NYSE:HPE
|
US |
|
B
|
Beiersdorf AG
XMUN:BEI
|
DE |
|
C
|
China Overseas Land & Investment Ltd
SWB:CPP
|
HK |
|
C
|
China Overseas Land & Investment Ltd
F:CPP
|
HK |
|
A
|
Advantest Corp
XMUN:VAN
|
JP |
|
F
|
Flutter Entertainment PLC
F:PPB
|
IE |
|
P
|
Pitney Bowes Inc
F:PBW
|
US |
|
C
|
China Overseas Land & Investment Ltd
XMUN:CPP
|
HK |
|
Alexander's Inc
F:AXE
|
US |
Wall St Price Targets
NKB2 Price Targets Summary
TG Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for NKB2 is 66.02 EUR with a low forecast of 17.94 EUR and a high forecast of 76.4 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NKB2's stock price target?
Price Target
66.02
EUR
According to Wall Street analysts, the average 1-year price target for NKB2 is 66.02 EUR with a low forecast of 17.94 EUR and a high forecast of 76.4 EUR.
What is the Revenue forecast for TG Therapeutics Inc?
Projected CAGR
22%
Over the last 13 years, the compound annual growth rate for Revenue has been 122%. The projected CAGR for the next 8 years is 22%.
What is the Gross Profit forecast for TG Therapeutics Inc?
Projected CAGR
23%
The compound annual growth rate for Gross Profit over the next 8 years is 23%.
What is the Operating Income forecast for TG Therapeutics Inc?
Projected CAGR
40%
The compound annual growth rate for Operating Income over the next 8 years is 40%.
What is the Pre-Tax Income forecast for TG Therapeutics Inc?
Projected CAGR
86%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 86%.
What is the Net Income forecast for TG Therapeutics Inc?
Projected CAGR
13%
The compound annual growth rate for Net Income over the next 5 years is 13%.
